A research and development (R&D) roadmap for broadly protective coronavirus vaccines: Setting a path to address coronavirus threats

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)6001-6003
Number of pages3
JournalVaccine
Volume40
Issue number42
DOIs
StatePublished - Oct 6 2022

Bibliographical note

Funding Information:
Drs. Moore, Osterholm, and Lackritz report no competing interests. Dr. Poland declares the following interests: Dr. Poland offers consultative advice on COVID-19 vaccine development to AstraZeneca, Pfizer, Medicago, Johnson&Johnson/Janssen, Novavax, and Moderna. Dr. Poland has received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine for which he holds a patent. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies.

Funding Information:
Funding for development of an R&D roadmap for broadly protective coronavirus vaccines is being provided by the Bill & Melinda Gates Foundation (Award number: INV-040729) and The Rockefeller Foundation (Award number: 2022 HTH 002). The authors would also like to acknowledge the CIDRAP team working on this project: Mr. Cory Anderson, Dr. Richard Danila, Ms. Tabitha Kazaglis, Ms. Angela Mehr, Ms. Julia Ostrowsky, and Dr. Angela Ulrich. We would also like to acknowledge the many technical experts who are contributing to development of the Coronavirus Vaccines R&D roadmap.

Keywords

  • Broadly protective coronavirus vaccines
  • COVID-19
  • Coronavirus
  • MERS-CoV
  • Pandemic preparedness
  • Roadmap
  • SARS-CoV-1
  • SARS-CoV-2

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this